Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2529人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866674, encodeId=5d2818666e414, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, objectType=article, longId=734132, objectId=690de34132b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=690de34132b5, replyNumber=0, likeNumber=85, createdTime=2022-12-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=690de34132b5, moduleTitle=J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=690de34132b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866589, encodeId=3ab1186658908, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, objectType=article, longId=724283, objectId=8cc1e24283bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cc1e24283bf, replyNumber=0, likeNumber=86, createdTime=2022-12-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cc1e24283bf, moduleTitle=J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cc1e24283bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866691, encodeId=315f186669165, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, objectType=article, longId=736047, objectId=95aee36047ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95aee36047ae, replyNumber=0, likeNumber=86, createdTime=2022-10-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95aee36047ae, moduleTitle=J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95aee36047ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866540, encodeId=1ecc1866540d3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！, objectType=article, longId=300545, objectId=1df2300545a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df2300545a4, replyNumber=0, likeNumber=109, createdTime=2022-12-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df2300545a4, moduleTitle=JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1df2300545a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866638, encodeId=f3881866638b7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, objectType=article, longId=729558, objectId=3e05e29558cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e05e29558cc, replyNumber=0, likeNumber=123, createdTime=2023-01-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e05e29558cc, moduleTitle=J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e05e29558cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866551, encodeId=0ac7186655141, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：pN1期前列腺癌根治术后适当的辅助放疗可降低长期死亡率！, objectType=article, longId=301062, objectId=76d130106266, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76d130106266, replyNumber=0, likeNumber=75, createdTime=2023-02-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76d130106266, moduleTitle=J Clin Oncol：pN1期前列腺癌根治术后适当的辅助放疗可降低长期死亡率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76d130106266)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866563, encodeId=2480186656323, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：肺癌患者性别的生存差异以及预后因素对其影响, objectType=article, longId=301403, objectId=2fa130140391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fa130140391, replyNumber=0, likeNumber=0, createdTime=2023-01-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa130140391, moduleTitle=J Thorac Oncol：肺癌患者性别的生存差异以及预后因素对其影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fa130140391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866603, encodeId=95e81866603af, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, objectType=article, longId=727300, objectId=7f29e2730032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f29e2730032, replyNumber=0, likeNumber=74, createdTime=2022-06-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f29e2730032, moduleTitle=Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f29e2730032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866669, encodeId=1364186666976, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Molecular Therapy-Oncolytics：李鹏/李扬秋合作发现提升CAR-T细胞抗异质性肿瘤活性新方法, objectType=article, longId=733032, objectId=c71fe3303267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c71fe3303267, replyNumber=0, likeNumber=0, createdTime=2023-02-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c71fe3303267, moduleTitle=Molecular Therapy-Oncolytics：李鹏/李扬秋合作发现提升CAR-T细胞抗异质性肿瘤活性新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c71fe3303267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866535, encodeId=0857186653555, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：鼻咽癌 | 选择性上颈部放疗是否可替代全颈放疗？, objectType=article, longId=300103, objectId=f14b30010366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f14b30010366, replyNumber=0, likeNumber=0, createdTime=2022-06-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f14b30010366, moduleTitle=Lancet Oncol：鼻咽癌 | 选择性上颈部放疗是否可替代全颈放疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f14b30010366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866652, encodeId=9d261866652a4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层 , objectType=article, longId=730534, objectId=206be305347e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=206be305347e, replyNumber=0, likeNumber=100, createdTime=2022-07-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=206be305347e, moduleTitle=Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=206be305347e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866622, encodeId=ef9e1866622c4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：小细胞肺癌颅内转移后的放疗选择, objectType=article, longId=728642, objectId=2292e28642df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2292e28642df, replyNumber=0, likeNumber=82, createdTime=2022-10-19, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2292e28642df, moduleTitle=Lancet Oncol：小细胞肺癌颅内转移后的放疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2292e28642df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866675, encodeId=371118666e567, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, objectType=article, longId=734225, objectId=0acbe3422547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0acbe3422547, replyNumber=0, likeNumber=106, createdTime=2023-06-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0acbe3422547, moduleTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0acbe3422547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866661, encodeId=048b18666617c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, objectType=article, longId=732001, objectId=e4e7e32001b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e7e32001b1, replyNumber=0, likeNumber=94, createdTime=2023-02-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e7e32001b1, moduleTitle=JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e7e32001b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866643, encodeId=9b641866643ee, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：I-II期黑色素瘤可能也需要进行辅助治疗, objectType=article, longId=729996, objectId=7189e2999604, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7189e2999604, replyNumber=0, likeNumber=119, createdTime=2022-10-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7189e2999604, moduleTitle=J Clin Oncol：I-II期黑色素瘤可能也需要进行辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7189e2999604)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866690, encodeId=1dc61866690b8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后, objectType=article, longId=736048, objectId=4468e3604828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4468e3604828, replyNumber=0, likeNumber=87, createdTime=2022-09-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4468e3604828, moduleTitle=J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4468e3604828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866587, encodeId=3472186658e3c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, objectType=article, longId=724175, objectId=74d6e2417552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d6e2417552, replyNumber=0, likeNumber=73, createdTime=2022-10-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d6e2417552, moduleTitle=J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d6e2417552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866676, encodeId=75c918666e624, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, objectType=article, longId=734319, objectId=1531e34319fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1531e34319fe, replyNumber=0, likeNumber=126, createdTime=2022-08-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1531e34319fe, moduleTitle=J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1531e34319fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866541, encodeId=c2101866541be, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：NAFLD相关肝细胞癌的临床特征及预后, objectType=article, longId=300612, objectId=96c030061203, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c030061203, replyNumber=0, likeNumber=110, createdTime=2022-09-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c030061203, moduleTitle=Lancet Oncol：NAFLD相关肝细胞癌的临床特征及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c030061203)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866548, encodeId=9d4c18665483a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效, objectType=article, longId=300810, objectId=d19e300810ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19e300810ee, replyNumber=0, likeNumber=90, createdTime=2022-10-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19e300810ee, moduleTitle=J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19e300810ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Encorafenib联合Binimetinib治疗BRAF V600突变型黑色素瘤的长期效益

2022-12-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：采用MEK抑制剂Selumetinib治疗携带MAPK通路变异的恶性肿瘤

2022-12-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：吉非替尼 vs 吉非替尼+卡铂+培美曲塞治疗EGFR突变的非小细胞肺癌

2022-10-21

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：仿制药HD201在ERBB2阳性乳腺癌中的疗效堪比曲妥珠单抗！

2022-12-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：mFOLFOXIRI方案联合帕尼单抗治疗RAS/BRAF野生型转移性结直肠癌

2023-01-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：pN1期前列腺癌根治术后适当的辅助放疗可降低长期死亡率！

2023-02-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：肺癌患者性别的生存差异以及预后因素对其影响

2023-01-15

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：Tiragolumab联合阿替利珠单抗作为一线方案治疗PD-L1阳性NSCLC

2022-06-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Molecular Therapy-Oncolytics：李鹏/李扬秋合作发现提升CAR-T细胞抗异质性肿瘤活性新方法

2023-02-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：鼻咽癌 | 选择性上颈部放疗是否可替代全颈放疗？

2022-06-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Int J Clin Oncol：前期接受醋酸阿比特龙和多西他赛治疗的转移性去势敏感前列腺癌患者的真实结果和风险分层

2022-07-02

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：小细胞肺癌颅内转移后的放疗选择

2022-10-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC

2023-06-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：阿特珠单抗、多西他赛、曲妥珠单抗和帕妥珠单抗新辅助治疗ERBB2阳性早期乳腺癌的效果

2023-02-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：I-II期黑色素瘤可能也需要进行辅助治疗

2022-10-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：埃罗妥珠单抗联合泊马度胺和地塞米松可显著改善复发/难治性多发性骨髓瘤生存预后

2022-09-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：索拉非尼联合标准化疗治疗FLT3/ITD+急性髓系白血病患儿的疗效和安全性

2022-10-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：HCT后采用Eprenetapopt+阿扎胞苷维持治疗TP53突变型AML和MDS的效益

2022-08-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：NAFLD相关肝细胞癌的临床特征及预后

2022-09-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：晚期尿路上皮癌患者采用纳武单抗定制疗法的临床疗效

2022-10-28

科室
- - 订阅+
  - 更多科室
工具
服务